Details of the Drug-Related molecule(s) Interaction Atlas

General Information of Drug (ID: DMCKPUR)

• Drug Name: Alfaferone Drug Info
• Synonyms: Alfaferon; Cilferon-A; Alpha-IFN, ASW; Interferon, ASW (alpha)

Indication

Disease Entry	ICD 11	Status	REF
Hairy cell leukaemia	2A82.2	Approved	[1]

• Cross-matching ID: TTD Drug ID: DMCKPUR

Molecule-Related Drug Atlas

Drug(s) Targeting Interferon alpha (IFNA)

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Interferon alfa-n3	DMTZNQ9	Human immunodeficiency virus infection	1C62	Approved	[3]
P1101	DM5DRMY	Polycythemia vera	2A20.4	Phase 3	[4]
Human interferon alpha oral	DMKQ3MC	Hepatitis C virus infection	1E51.1	Phase 2	[5]
IFN-alpha	DM4H8EZ	Hepatitis C virus infection	1E51.1	Phase 2	[6]
Rontalizumab	DMBJN19	Systemic lupus erythematosus	4A40.0	Phase 2	[7]
Interferon-alpha lozenge	DM8YF01	Behcet disease	4A62	Phase 2	[8]
IFN alpha kinoid	DMLEVFW	Human immunodeficiency virus infection	1C62	Phase 1/2	[9]
NG-641	DMITVHM	Solid tumour/cancer	2A00-2F9Z	Phase 1	[10]
AGS-009	DMU21JF	Systemic lupus erythematosus	4A40.0	Phase 1	[11]
Ad-IFN-alpha	DMM45P9	Bladder cancer	2C94	Phase 1	[12]

Molecular Interaction Atlas of This Drug

Drug Therapeutic Target (DTT)

DTT Name	DTT ID	UniProt ID	MOA	REF
Interferon alpha (IFNA)	TT95SOA	NOUNIPROTAC	Modulator	[2]

References

• [1] Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
• [2] Natural leukocyte interferon alpha (Alfaferone) combined with ribavirin in the treatment of patients with HCV-related cirrhosis: our experience. Infection. 2011 Oct;39(5):433-7.
• [3] Clinical pipeline report, company report or official report of Hemispherx Biopharma.
• [4] Molecular responses and chromosomal aberrations in patients with polycythemia vera treated with peg-proline-interferon alpha-2b. Am J Hematol. 2015 Apr;90(4):288-94.
• [5] Low-dose oral natural human interferon-alpha in 29 patients with HIV-1 infection: a double-blind, randomized, placebo-controlled trial. AIDS. 1992 Jun;6(6):563-9.
• [6] WO patent application no. 2009,0153,36, Controlled release interferon drug products and treatment of hcv infection using same.
• [7] Clinical pipeline report, company report or official report of Genentech (2011).
• [8] Interferon-alpha. Amarillo Biosciences. Curr Opin Investig Drugs. 2002 May;3(5):693-7.
• [9] Down-regulation of interferon signature in systemic lupus erythematosus patients by active immunization with interferon alpha-kinoid. Arthritis Rheum. 2013 Feb;65(2):447-56.
• [10] Clinical pipeline report, company report or official report of PsiOxus Therapeutics.
• [11] Emerging Therapies for Systemic Lupus Erythematosus - Focus on Targeting Interferon-alpha. Clin Immunol. 2012 June; 143(3): 210-221.
• [12] 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.